| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/28/2008 | US20080051691 Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
| 02/28/2008 | US20080051460 Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| 02/28/2008 | US20080051459 Long term 24-hour intestinal administration of levodopa/carbidopa |
| 02/28/2008 | US20080051458 Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use |
| 02/28/2008 | US20080051456 Glycine Reuptake Inhibitors for Treatment of Drug Dependence |
| 02/28/2008 | US20080051441 Aryl Sulphonamide Modulators |
| 02/28/2008 | US20080051437 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| 02/28/2008 | US20080051436 Use of Acylaminothiazole Derivatives as Therapeutic Agents |
| 02/28/2008 | US20080051433 Pyrrole-3-Carboxamide Derivatives for the Treatment of Obesity |
| 02/28/2008 | US20080051426 9-fluoro-3,3,6-trimethyl-2,3,4,7-tetrahydroindolo[2,3-c]quinolin-1-one; reacting substituted 1-oxo-2,3,4,7-tetrahydro-1H-5-oxonia-7-azabenzo[c]fluorene perchlorates, dihydrophosphates or tetrafluoroborates with ammonium hydroxide or ammonium acetate; ischemia-reperfusion injury; antidepressant |
| 02/28/2008 | US20080051421 pyrazolo- and imidazo-pyrimidine derivatives; for anxiety and pain, neurodegenerative disorders; 8-Pyridin-4-yl-4-trifluoromethyl-2-(4-trifluoromethyl-phenyl)-imidazo[1,5-a]pyrimidine |
| 02/28/2008 | US20080051420 New Compounds 317 |
| 02/28/2008 | US20080051415 Novel piperazines, pharmaceutical compositions and methods of use thereof |
| 02/28/2008 | US20080051409 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof |
| 02/28/2008 | US20080051405 Therapeutic Agents |
| 02/28/2008 | US20080051403 Treatment For Alzheimer's Disease And Related Conditions |
| 02/28/2008 | US20080051398 Method of treating brain cancer |
| 02/28/2008 | US20080051397 with polyglycolized glyceride (macrogol glyceride); Gelucires"; multiple sclerosis, asthma, scleroderma, endometriosis; 1,3-benzothiazol-2(3H)-ylidene{2-[(1,4-dimethylpiperazin-2-yl)methoxy]pyrimidin-4-yl}acetonitrile; adding to melt as powder under stirring resulting in homogeneous molten dispersion |
| 02/28/2008 | US20080051394 6H-Oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 02/28/2008 | US20080051390 Such as 8-[3-(2-Fluoropyridin-3-yl)phenyl]-8-pyridin-4-yl-2,3,4,8-tetrahydroimidazo[1,5-a]pyrimidin-6-amine; amyloid disorders, Alzheimer's disease, Down's syndrome |
| 02/28/2008 | US20080051387 Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| 02/28/2008 | US20080051372 Methods utilizing cell-signaling lysophospholipids |
| 02/28/2008 | US20080051366 Aminosugar, glycosaminoglycan, and s-adenoslymethionine composition for the treatment and repair of connective tissue |
| 02/28/2008 | US20080051363 G-rich polynucleotides as a novel therapeutic for the treatment of huntington's disease |
| 02/28/2008 | US20080051358 using CLN2 protein having pepstatin-insensitive carboxyl protease activity to treat LINCL; mutation or absence of CLN2 is causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL) |
| 02/28/2008 | US20080051357 Composition for attenuating neuropathic pain comprising a recombinant ventor expressing gad65 |
| 02/28/2008 | US20080051339 Modulators of pharmacological agents |
| 02/28/2008 | US20080051338 98 Human Secreted Proteins |
| 02/28/2008 | US20080051334 Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases |
| 02/28/2008 | US20080051319 Inhibiting JNK Signaling Promotes CNS Axon Regeneration |
| 02/28/2008 | US20080051318 Detecting single nucleotide polymorphism ; kits; drug screening; neurodegenerative disease |
| 02/28/2008 | US20080050457 Ginkgo Biloba Extract And Method For Producing The Same |
| 02/28/2008 | US20080050431 Sustained release formulations of oxymorphone |
| 02/28/2008 | US20080050427 Analgesic combination of tramadol and meloxicam |
| 02/28/2008 | US20080050424 Transdermal therapeutic system for treating parkinsonism |
| 02/28/2008 | US20080050383 Immunotherapy for clearing pathological tau conformers |
| 02/28/2008 | US20080050368 Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith |
| 02/28/2008 | US20080050367 Humanized antibodies that recognize beta amyloid peptide |
| 02/28/2008 | US20080050315 Diagnostics and Therapeutics for Diseases Associated with Protein Kinase, Cgmp-Dependent, Type I (Prkg1) |
| 02/28/2008 | US20080050314 Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b) |
| 02/28/2008 | CA2697675A1 Intrathecal administration of triptan compositions to treat non-migraine pain |
| 02/28/2008 | CA2661898A1 Indazole derivatives that inhibit trpv1 and uses thereof |
| 02/28/2008 | CA2661558A1 Biomarkers for alzheimer's disease progression |
| 02/28/2008 | CA2661553A1 Method of treating or preventing oxidative stress-related disease |
| 02/28/2008 | CA2661307A1 Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr) |
| 02/28/2008 | CA2661220A1 Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
| 02/28/2008 | CA2661187A1 Piperidine derivatives |
| 02/28/2008 | CA2661054A1 Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 02/28/2008 | CA2660957A1 2-phenoxy pyrimidinone analogues |
| 02/28/2008 | CA2660515A1 Synthesis, polymorphs, and pharmaceutical formulation of a faah inhibitor |
| 02/28/2008 | CA2660169A1 Fluorinated ligands for targeting peripheral benzodiazepine receptors |
| 02/27/2008 | EP1892299A2 Sense mRNA therapy |
| 02/27/2008 | EP1892251A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 02/27/2008 | EP1892239A1 Inhibitors of cytosolic phospholipase A2 |
| 02/27/2008 | EP1892238A1 1, 2-di(cyclic group)substituted benzene derivative |
| 02/27/2008 | EP1891975A1 Anti-allergic complex molecules |
| 02/27/2008 | EP1891969A2 Novel anti-allergic agents |
| 02/27/2008 | EP1891962A1 Glutathione based delivery system |
| 02/27/2008 | EP1891956A1 Solubilization preparation |
| 02/27/2008 | EP1891948A1 Treatment of neurological and neuropsychological disorders |
| 02/27/2008 | EP1891946A1 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone |
| 02/27/2008 | EP1891114A2 Anti-trkb monoclonal antibodies and uses thereof |
| 02/27/2008 | EP1891073A1 Novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives and their use as a medicament |
| 02/27/2008 | EP1891068A1 Triazolopyridine derivatives as cannabinoid receptor 1 antagonists |
| 02/27/2008 | EP1891065A1 Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders |
| 02/27/2008 | EP1891064A1 N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as ccr1 antagonists |
| 02/27/2008 | EP1891057A1 Azab i cyclo [3 . 1 . 0] hexane derivatives as dopamin d3 receptor modulators |
| 02/27/2008 | EP1891056A1 Novel compounds |
| 02/27/2008 | EP1891041A1 METABOLITES OF 1- [-6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL]-3- [2- (4-METHYL-PIPERAZIN-I-YL) -BENZYL]-PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS |
| 02/27/2008 | EP1891035A1 Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs |
| 02/27/2008 | EP1891012A2 Quinoline derivatives as nk3 anatgonists |
| 02/27/2008 | EP1891008A1 Oxindoles as kinase inhibitors |
| 02/27/2008 | EP1891006A2 Inhibitors of cytosolic phospholipase a2 |
| 02/27/2008 | EP1891002A1 Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |
| 02/27/2008 | EP1890995A2 Synthesis of organic compounds |
| 02/27/2008 | EP1890701A1 Composition for the treatment of multiple sclerosis |
| 02/27/2008 | EP1890700A2 Methods and compositions for managing psychotic disorders |
| 02/27/2008 | EP1890697A2 Azinone and diazinone v3 inhibitors for depression and stress disorders |
| 02/27/2008 | EP1890689A2 Composition for slowing down the development of alzheimer's disease |
| 02/27/2008 | EP1890685A2 Pharmaceutical formulations of amyloid inhibiting compounds |
| 02/27/2008 | EP1890684A1 Treatment of sleep-wake disorders |
| 02/27/2008 | EP1890678A2 Therapeutic sclerosing foam made preferably xenon |
| 02/27/2008 | EP1802307B1 Pyrrolidine derivatives as histamine receptors ligands |
| 02/27/2008 | EP1773810B1 New 4-benzylidene-piperidin derivatives |
| 02/27/2008 | EP1610786B9 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's |
| 02/27/2008 | EP1532155B1 C6- AND C9-SUBSTITUTED CHROMENO[4,3-c]ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS |
| 02/27/2008 | EP1509251B1 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 02/27/2008 | EP1506192B1 Substituted pyrroline kinase inhibitors |
| 02/27/2008 | EP1496873B1 Chewable soft capsule |
| 02/27/2008 | EP1483266B1 Spiro compounds with npy antagonistic activity |
| 02/27/2008 | EP1453827B1 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| 02/27/2008 | EP1446115B1 Cyanoalkylamino derivatives as protease inhibitors |
| 02/27/2008 | EP1438393B1 Differentiation of whole bone marrow |
| 02/27/2008 | EP1318994B1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 02/27/2008 | EP1282700B1 Neuronal serine-threonine protein kinase |
| 02/27/2008 | EP1246806B1 Arly- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 02/27/2008 | EP1150959B1 Solid-state form of celecoxib having enhanced bioavailability |
| 02/27/2008 | EP1149105B1 4,5-pyrazinoxindoles as protein kinase inhibitors |
| 02/27/2008 | EP1141278B1 Therapeutic pde4d phosphodiesterase inhibitors |
| 02/27/2008 | EP0896578B1 NOVEL IMIDAZO[1,5-c]QUINAZOLINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS |